Skip to main content

Financial News

  • Retail execs optimistic about 2017 in survey
    Retailers executives are bullish on 2017.
     
    That’s according to a survey from TD Bank, which polled 173 retail executives at the National Retail Federation’s annual Big Show in New York City. Seventy-four percent of the retailers said they believe sales will increase in the next 12 months. What’s more, 81% of the retailers reported that they met or exceeded their revenue goals in 2016.
     
    In other key findings:

  • J&J exploring strategic options for LifeScan unit

    NEW BRUNSWICK, N.J.  — Johnson and Johnson on Tuesday announced it will be evaluating "potential strategic options" for its LifeScan diabetes business, as well as other J&J diabetes banners including Animas Corp. and Calibra Medical.

    The news was announced in conjunction with the company's fourth quarter earnings call, and is part of the company's ongoing portfolio management.

  • Federal judge blocks Aetna, Humana merger, citing competition concerns
    WASHINGTON — The proposed $37 billion merger between Aetna and Humana hit a roadblock Monday, when U.S. District Court Judge John Bates issued his ruling in a lawsuit between the companies and the federal government. The Dept. of Justice sued on behalf of 264 counties in 21 states where it said a merger would limit competition unlawfully in the Medicare Advantage markets and 17 counties in three states where it said public exchange competition would be limited.
     

  • Analyst: Walgreens' Rite Aid deal still on point

    NEW YORK — Challenging "vague" reports suggesting the Walgreens deal to acquire Rite Aid may be in jeopardy, Deutsche Bank on Friday issued a research note outlining the number of options Walgreens still has at its disposal leading up to the Jan. 27 deadline.

  • Teva completes sale of U.K., Ireland Actavis business to Intas’s Accord Healthcare
    JERUSALEM and AHMEDABAD, India — The sale of Teva’s Actavis U.K. and Actavis Ireland to Intas Pharmaceuticals through its subsidiary Accord Healthcare for £603 million, Intas announced Tuesday. The transaction is part of the European Commission’s antitrust divestiture requirements surrounding Teva’s acquisition of Allergan’s generics business. 
     

  • Takeda to acquire Ariad Pharmaceuticals
    CAMBRIDGE, Mass. And OSAKA, Japan — Takeda on Monday announced its plan to acquire Ariad Pharmaceuticals for approximately $5.2 billion. The boards of both companies unanimously approved the transaction, and the companies expect it to close by the end of February. 
     

  • Multivitamins still provide plenty of opportunities via gummies, probiotics

    Overall, sales of multivitamins are relatively flat — 0.2% annual growth toward a $1.8 billion base. But according to the latest consumer survey from the Council for Responsible Nutrition, 3-in-4 adults use a multivitamin. So, have sales of multivitamins plateaued, or are there pockets of opportunity out there?

  • Jean Coutu Group sales up 1.9% despite generic pressures

    VARENNES, Québec  — The Jean Coutu Group on Friday posted a 1.9% increase in revenues to $576.8 million for the quarter ended Nov. 26.

X
This ad will auto-close in 10 seconds